![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The prognosis for those with relapsed Hodgkin lymphoma is poor. This evaluation is of two new approaches to the treatment of relapsed Hodgkin lymphoma. First, is a refinement of the chemotherapy for the relapsed condition, which showed that adding SHDCT (sequential high-dose chemotherapy of cyclophosphamine, uromitexane, granulocyte colony-stimulating factor, methotrexate, vincristine, etoposide) did not improve outcome. Second, is new targeted treatment for relapsed Hodgkin disease – brentuximab vedotin, which has an antitubulin agent (monomethylauristatin E) attached to a CD30-specific antibody. This agent gave promising results in a Phase I clinical trial in subjects with relapsed Hodgkin lymphoma. Brentuximab vedotin has produced good initial findings in the treatment of Hodgkin lymphoma and needs to be tested more widely.